文献速递间质性肺疾病肺结节与肺癌

癌症靶向单抗相关间质性肺病不良事件报告的全球失衡性分析(1968-2024)

Global Disproportionality Analysis of Adverse Event Reports on Interstitial Lung Diseases for Cancer-Targeted Therapies, 1968-2024.
PubMed 文献 · Respirology · 2025-10-21

该全球药物警戒研究对癌症靶向单抗相关间质性肺病(ILD)亚型进行失衡性分析,纳入VEGF/VEGFR、CD20、PD-1/PD-L1、HER2和EGFR抑制剂五类单抗。结果显示间质性肺炎和肺纤维化在各药物中均呈显著报告信号,其中EGFR抑制剂和PD-1/PD-L1抑制剂的间质性肺炎信号最强,CD20抑制剂的肺纤维化信号较高。

要点

  • 间质性肺炎和肺纤维化在所有纳入的癌症靶向单抗中均显示显著失衡报告信号。
  • EGFR抑制剂和PD-1/PD-L1抑制剂的间质性肺炎报告信号最强。
  • PD-1/PD-L1抑制剂的机化性肺炎信号最强,嗜酸性肺炎除CD20外均有信号。

核心结论

  • 该全球失衡性研究提示癌症靶向单抗与ILD亚型之间存在报告信号,但不能进行因果推断。
  • 研究强调在单抗给药前后加强不良事件报告系统的重要性。

研究设计与样本

  • 全球药物警戒研究,采用失衡性分析检测癌症靶向单抗相关ILD亚型的报告信号。
  • ILD亚型按既往研究分为八类,排除报告数少的四类,最终分析四类亚型。
  • 纳入五类癌症靶向单抗:VEGF/VEGFR、CD20、PD-1/PD-L1、HER2和EGFR抑制剂(ATC代码L01F)。
  • 使用报告比值比(ROR)及95%CI和信息成分(IC)及IC025评估报告信号。

主要发现

  • 间质性肺炎和肺纤维化在所有药物中均显示显著失衡报告信号。
  • 间质性肺炎与EGFR抑制剂相关:ROR 47.46(95%CI 44.67-50.42),IC 5.47(IC0.25 5.37)。
  • 间质性肺炎与PD-1/PD-L1抑制剂相关:ROR 45.20(95%CI 43.49-46.97),IC 5.36(IC0.25 5.30)。
  • 肺纤维化与CD20抑制剂相关:ROR 12.71(95%CI 11.30-14.31),IC 3.61(IC0.25 3.42)。
  • 机化性肺炎与PD-1/PD-L1抑制剂相关:ROR 44.48(95%CI 39.05-50.67),IC 5.26(IC0.25 5.04),信号最强;随后为CD20抑制剂ROR 17.45(95%CI 13.88-21.94),IC 3.95(IC0.25 3.57);HER2抑制剂ROR 15.95(95%CI 11.88-21.40),IC 3.76(IC0.25 3.26)。

关键数值与推荐

  • 间质性肺炎:EGFR抑制剂ROR 47.46(95%CI 44.67-50.42),IC 5.47(IC0.25 5.37)。
  • 间质性肺炎:PD-1/PD-L1抑制剂ROR 45.20(95%CI 43.49-46.97),IC 5.36(IC0.25 5.30)。
  • 肺纤维化:CD20抑制剂ROR 12.71(95%CI 11.30-14.31),IC 3.61(IC0.25 3.42)。
  • 机化性肺炎:PD-1/PD-L1抑制剂ROR 44.48(95%CI 39.05-50.67),IC 5.26(IC0.25 5.04)。
  • 嗜酸性肺炎:除CD20抑制剂外所有药物均显示显著报告信号。

临床怎么用

  • 对使用VEGF/VEGFR、CD20、PD-1/PD-L1、HER2和EGFR抑制剂的患者,应警惕间质性肺炎和肺纤维化等ILD亚型。
  • 使用EGFR抑制剂或PD-1/PD-L1抑制剂时,间质性肺炎报告信号强,需加强监测。
  • 使用PD-1/PD-L1抑制剂时,机化性肺炎信号最强,应予以关注。
  • 使用CD20抑制剂时,肺纤维化信号相对较高,需注意识别。
  • 在单抗给药前后加强不良事件报告系统,有助于早期发现ILD信号。

局限性

  • 该研究为失衡性分析,不能进行因果推断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The increasing complexity of interstitial lung disease (ILD) related to cancer-targeted monoclonal antibodies (mAbs) has emerged as a significant clinical concern. Thus, this study aimed to investigate reporting signals of four ILD subtypes detected with cancer-targeted mAbs. METHODS: This global pharmacovigilance study conducted disproportionality analyses to detect signals of ILD subtypes reported with cancer-targeted mAbs. ILD subtypes were classified into eight categories according to previous studies, of which four with a low number of reports were excluded. Five cancer-targeted monoclonal antibodies (VEGF/VEGFR, CD20, PD-1/PD-L1, HER2, and EGFR inhibitors) were included according to ATC code (L01F). Reporting signals were evaluated using reporting odds ratio (ROR) with 95% CI and information component (IC) with IC025. RESULTS: Interstitial pneumonitis and pulmonary fibrosis showed significant disproportionate reporting signals across all drugs. Notably, interstitial pneumonitis showed significant signals with EGFR inhibitors (ROR, 47.46 [95% CI, 44.67-50.42]; IC, 5.47 [IC0.25, 5.37]) and PD-1/PD-L1 inhibitors (45.20 [43.49-46.97]; 5.36 [5.30]), while pulmonary fibrosis showed higher signals with CD20 inhibitors (12.71 [11.30-14.31]; 3.61 [3.42]). Organising pneumonia exhibited significant signals with PD-1/PD-L1 inhibitors (ROR, 44.48 [95% CI, 39.05-50.67]; IC, 5.26 [IC0.25, 5.04]), followed by CD20 (17.45 [13.88-21.94]; 3.95 [3.57]), and HER2 (15.95 [11.88-21.40]; 3.76 [3.26]), with the strongest signal observed with PD-1/PD-L1 inhibitors. Eosinophilic pneumonia showed significant signals with all drugs except CD20 inhibitors. CONCLUSIONS: Although causal inference cannot be drawn, this global disproportionality study highlights reporting signals between cancer-targeted mAbs and ILD subtypes, underscoring the importance of strengthening adverse event reporting systems before and after mAb administration.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Jeong J, Kim H, Lee S, et al. Global Disproportionality Analysis of Adverse Event Reports on Interstitial Lung Diseases for Cancer-Targeted Therapies, 1968-2024. Respirology. 2025. PMID: 41121456. doi:10.1002/resp.70135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。